FluroTech Ltd. (TSXV: TEST) and its subsidiary FluroTest Diagnostics Systems announced today that the clinical trials for its high volume COVID-19 rapid antigen testing system are pushing to its next phase. This trial is being conducted with contract research organization Toolbox Medical Innovations.
FluroTest reported that approximately 600 volunteer participants are currently being identified from six clinical sites across California, Texas, Colorado, Rhode Island, and Florida for the next phase of the trial. The participants are a mix of symptomatic and asymptomatic individuals and the identified sites will compare the diagnostic results from the company’s high volume antigen testing system and a comparator RT-PCR assay.
As reported previously, the clinical trial results will be used to apply for an emergency use authorization from the U.S. FDA and an interim order authorization from the Health Canada.
FluroTech Ltd. last traded at $0.31 on the TSX Venture.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
